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Introduction
First line regimens for the treatment of adult acute leukemias are
highly effective in achieving initial remission, however, relapse is seen
in about half of cases [1]. Around 20–30% of these cases are refractory
to conventional treatment, becoming a challenging domain for the
heme-oncologists [2, 3]. The primary strategy for these cases is rein
duction chemotherapy followed by allogenic stem cell transplantation
[4, 5]. Fludarabine, a purine nucleotide analog, has recently become the
focus of treatment for acute leukemias and myelodysplastic syndromes
(MDS). Its active metabolite, Fludarabine triphosphate, inhibits ribo
nucleotide reductase with subsequent accumulation of intracellular
cytosine arabinoside (AraC) triphosphate [6, 7].
The toxicity profile of Fludarabine has been shown to be acceptable
[8], but it is often combined with additional agents to improve efficacy
and limit untoward toxicity [9-11]. The combination of Fludarabine
with Ara-C increases the intracellular Ara-C content by two- to
seven-fold in leukemic cells, which has shown a positive correlation with
remission rates [12]. Idarubicin (IDA), an anthracycline, is also added
because of its less susceptibility to multidrug resistance compared to
other anthracyclines in human leukemia cell lines; and have lesser
cardiotoxicity making them favorable for heavily pretreated patients
[13, 14]. Granulocyte colony stimulating factor (G-CSF) prior to Flu
darabine increases the fraction of cells in cycle when they are most
vulnerable to AraC, and enhances the incorporation of AraC into DNA
[15, 16].
The synergistic action of Fludarabine, AraC and IDA with or without
G-CSF (abbreviated as FLAG-IDA and FLA-IDA respectively) have found
widespread use as salvage chemotherapy for refractory/relapsed Acute
Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)
with complete remission rates ranging from 40–60% with variable 30day mortalities ranging from 4% to 9% [4, 5, 17, 18]. Additionally, a

recent retrospective trial by Farooq et al. [19] compared outcomes in 76
patients treated for FLAG-IDA and FLAG; and found a significant
improvement in survival in patients treated for Fludarabine-based
regimen without IDA [19].
However, a small single-center study from Pakistan by Hashmi et al.
[20] found a much higher 30-day mortality rate of 25% (3/12 patients)
with FLAG-IDA and similar complete remission rates (66%). Hence, the
purpose of our study is to identify the 30-day mortality rate in a larger
cohort of patients with ALL/AML being treated with Fludarabine-based
regimens in a single tertiary care center in Pakistan. Additionally, we
aim to compare outcomes in adult patients with ALL/AML being treated
with Fludarabine-based regimens with and without G-CSF, since this
comparison has previously been performed without the addition of IDA
in treatment regimens [9]. We hypothesize the 30-day mortality rate
with Fludarabine-based regimens will be lower than the previously
published 25% and there will be a significant difference in
post-treatment outcomes between patients being treated with FLA-IDA
and FLAG-IDA.
Methods
This retrospective cohort study was reviewed and approved by the
Aga Khan University Hospital Ethical Review Committee. Electronic
medical records were searched from January 2015 to November 2020
from one tertiary university hospital in Karachi.
Study population
Medical records were searched for male and female adult patients
being treated with Fludarabine-based therapy for: 1) Refractory/Relapse
ALL; 2) Refractory/Relapse AML; or 3) Acute Leukemia transforming
from MDS and Chronic Myeloid Leukemia refractory to or relapsing after
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first line regimen. Patients were excluded if they: 1) were <18 years or
>60 years of age; 2) had ECOG status >2 [21]; 3) had severe organ
damage defined as alanine transaminase (ALT) >2.0x normal or creat
inine >2.0x normal or cardiac ejection fraction <60%; or 4) had pre
viously been on Fludarabine-based treatment.

respectively. Patients who had remission but did not have a relapse
during the 3-month follow-up period were censored at Day 90 and
labeled as not having failure of treatment. Survival analysis was per
formed using a Log-rank test comparing the equity of survival functions.
A p-value of 0.05 was considered significant and analysis was performed
on R Programming Language [25].

Data collection

Results

The following demographics were extracted from medical records:
patient age, sex, refractory/relapse acute leukemia (ALL or AML), mo
lecular genetic risk factors (FLT3 for AML and BCR ABL for ALL), cy
togenetic risk factor and clinical risk stratification (high or low on ALL or
AML risk stratification score) [22, 23]. The following post-intervention
variables were extracted: 1) complete remission on day 28 of chemo
therapy; 2) incidence of early death (defined as death within 4 weeks of
chemotherapy); 3) incidence of relapse at 30 days, 60 days and 90 days
after achieving complete remission at the end of 4-week of treatment;
and 4) toxicity profile according to the Common Terminology Criteria
for Adverse Events (CTCAE) which included nausea, vomiting, diarrhea,
anemia, hepatotoxicity and nephrotoxicity [24].

From January 2015 to November 2020, 39 patients were diagnosed
with refractory/ relapsing acute leukemias and were treated with
fludarabine-based therapy. Patients were a mean of 34.6 ± 10.6 years
(range 19 – 55 years) and were 77% male. One patient left against
medical advice before treatment and was not included in analysis. Three
patients died during the chemotherapy regimen and were considered as
Early Death during intervention, leading to a 30-day mortality rate of
8% (3/38). Out of the 38 patients, 17 were treated with FLA-IDA and 21
were treated with FLAG-IDA. All patients had undergone bone marrow
cytogenetics at baseline. Patients with no abnormality in karyotype were
considered normal in cytogenetic analysis, while those with one or more
abnormalities, including complex karyotype were counted as abnormal.
63% (24/38) patients in the study had at least one abnormality in their
karyotype.
Molecular genetic risk was based on the presence of FLT3-ITD mu
tation in acute myeloid leukemia patients and BCR-ABL fusion in acute
lymphoblastic leukemia patients. FLT3-ITD was positive in 5% (1/19) of
all AML patients while BCR-ABL was positive in 23.8% (5/21) of the ALL
patients in our sample population. NPM1 mutation was found to be
positive in 10% (2/20) of AML patients. NPM1, FLT3-ITD mutation and
BCR-ABL fusion was performed by RT-PCR technique. Patients did not
differ in age, sex, primary diagnosis, history of refractory disease, clin
ical risk stratification, cytogenetic analysis or molecular genetic risk.
Group wise patient demographics are presented in Table 1.
When comparing outcomes between regimens, 1 patient in the FLAIDA group and 2 in the FLAG-IDA group died within 4 weeks of inter
vention; hence only 16 patients in FLA-Ida and 19 in the FLAG-Ida group
were included in all subsequent outcome comparisons. Groups did not
significantly differ in post-therapy outcomes or toxicity profile, except
FLA-IDA had a significantly higher proportion of hepatotoxicity than
FLAG-IDA (p = 0.006) post-therapy. There were no clinical features
including co-morbidities, viral infections or underlying disease that
could be attributed to the hepatotoxicity in the FLA-IDA group. It was an
incidental finding that was noticed during the retrospective analysis in
the study. Group wise outcomes are presented in Table 2.

Fludarabine-based treatment regimens
Patients were divided into the following groups based on chemo
therapy regimen received:
FLA-IDA: This regimen included intravenous Fludarabine given at
30 mg/m2/day in a 30-minute infusion (for Day 1–5), then 4 h later with
intravenous AraC at 2 g/m2/day (for Day 1–5) in a 4-hour infusion and
intravenous IDA at 8 mg/m2/day (for Day 1–3) as a 30-minute infusion.
These patients did not receive G-CSF throughout the course of
treatment.
FLAG-IDA: This regimen also included Fludarabine (30 mg/m2/day
for Day 1–5), AraC (2 g/m2/day for Day 1–5) and IDA (8 mg/m2/day for
Day 1–3); with the addition of subcutaneous G-CSF from Day 1 to until
absolute neutrophil count (ANC) of 500/mL.
Main outcome measure and definitions
The following outcome measures are recorded:
Complete remission: Defined as having peripheral blood counts
within normal limits plus bone marrow blast percentage <5% at Day 28
bone marrow biopsy.
Relapse: Defined as having >5% blasts in the bone marrow at either
Day 30, 60 or 90 after achieving complete remission on Day 28 bone
marrow biopsy.
Refractory disease: Defined as having persistence of blast cells in
peripheral blood and/or >5% bone marrow blast cells at Day 28 bone
marrow biopsy.

Table 1
Sample group-wise demographics.

Statistical analysis

Age

Analysis was based on per protocol analysis. Univariate statistics
were performed and 30-day mortality was calculated for the entire
sample. Patients were categorized in the following groups based on
treatment regimens; FLA-IDA or FLAG-IDA. Group wise comparisons
were performed, continuous variables were compared using nonparametric t-tests and categorical variables were compared using χ2
test (Fisher’s Exact for group n <5). Groups were compared on initial
presentation characteristics and post-therapy outcomes. A binary lo
gistic regression model was built with stepwise selection to identify
initial presentation characteristics and treatment regime that would be
predictive of complete remission on Day 28 of chemotherapy. A Kaplan
Meier life table stratified by treatment regime was made. Patients who
did not have remission were labeled as failure during treatment. Patients
who had remission on the Day 28 biopsy but had a relapse on subsequent
follow-up visits were label as failure on Day 30, 60 or 90 post-remission

Sex
Primary Diagnosis

Primary Leukemia Type
Cytogenetic Analysis
Molecular Genetic Risk
History of Refractory
Disease
Clinical Risk Stratification

2

FLA-Idan ¼ 17

FLAG-Idan ¼ 21

pvalue

35.65 ± 10.8
years
5 female, 12 male
8 de novo AML
6 de novo B-ALL
3 de novo T-ALL
1 secondary BALL

34.29 ± 10.5
years
4 female, 17 male
9 de novo AML
4 de novo B-ALL
5 de novo T-ALL
1 secondary BALL
1 tdT +
lymphoma
1 myeloid
sarcoma
10 myeloid
11 lymphoid
12 abnormal
4 high risk
6 refractory
disease
16 high risk

0.772

8 myeloid
9 lymphoid
12 abnormal
2 high risk
2 refractory
disease
10 high risk

0.703
0.739

0.973
0.393
0.672
0.257
0.307
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Table 2
Post-therapy Outcomes by Treatment Regime.

Early Death
Febrile
Nausea
Vomiting
Diarrhea
Hepatotoxicity
Nephrotoxicity
Allergy
Anemia
Complete Remission after therapy
Relapse within 90 days after
Remission

FLA-IDAn ¼
17

FLAG-IDAn ¼
21

pvalue

1/17
16/16 Grade 3
2/16 Grade 2
1/16 Grade 3
1/16 Grade 3
1/16 Grade 3
5/16 Grade 1
2/16 Grade 2
1/16 Grade 3
–

2/21
19/19 Grade 3
2/19 Grade 2

>0.999
–
0.526

1/19 Grade 2
–
–

0.362
0.457
0.006

1/19 Grade 1
1/19 Grade 2
–
6/19 Grade 1
10/19 Grade 2
3/19 Grade 3
8/19
4/8

0.409

–
5/16 Grade 1
4/16 Grade 2
7/16 Grade 3
10/16
5/10

–
0.133
0.229
–

On logistic regression, not having a molecular genetic risk factor was
the only significant predictor of complete remission after treatment with
Fludarabine-based regimens. Of note, type of Fludarabine-based
regimen was not a predictor for complete remission (β = 1.00, p =
0.309). Results of logistic regression are presented in Table 3.
Lastly, there was no significant difference in survival between
Fludarabine-based regimens up to Day 90 (p = 0.671). About 60% of
patients in the FLAG-IDA group and 40% of FLA-IDA did not achieve
complete remission after therapy, and showed similar patterns of re
lapses up to Day 90. Kaplan Meier life table showing cumulative survival
are presented in Fig. 1.

Fig. 1. Kaplan Meier life table stratified by Fludarabine-based treatment
regimen. Log rank test comparing survival function χ 2 = 0.18, p = 0.671.

treatment is discontinued [26].
When investigating pre-treatment demographics and clinical risk
factors that would be predictive of remission after 4 weeks of
Fludarabine-based chemotherapy, our analysis found the presence of
molecular genetic risk factors (FLT3 for AML and BCR-ABL for ALL) to be
predictive of poor outcomes. FLT3 is a FMS-like tyrosine kinase gene
mutation and is present in about 30% of patients with AML, and is
associated with shorter remission duration and higher relapse rates
compared with patients without the mutation [27]. Similarly, the
presence of the fusion of BCR-ABL is present in about 30% of patients
with ALL and is associated with a lower chance of initial treatment
response and a lower probability of disease-free survival [28]. Other
variables, such as clinical risk stratification, patient gender and leuke
mia type (lymphoid versus myeloid), were showing a trend in our lo
gistic regression, however, our sample size is not large enough to make
meaningful conclusions. Larger, adequately powered studies are
required in the future to investigate which demographic and clinical risk
factors are most predictive of treatment success during the 4-week
intervention.
Advancements in treatment of de novo acute leukemias are under
way. First line regimens commonly used in our setting are AraC and IDA
as 7 + 3 regimen in AML while the UK-ALL XII protocol is used for ALL
patients [29]. Yet, the treatment of refractory/relapsed leukemias are a
difficult domain due to low response rate, shorter duration of remission,
high treatment related mortality and narrow range of therapeutics
available, and the best modality of treatment is to do an allogenic stem
cell transplant [4, 5]. For these reasons, salvage chemotherapy like
Fludarabine in combination with other chemotherapeutics with an
acceptable toxicity profile is highly useful for bridging patients to stem
cell transplant or at least help them achieve second remission that can be
followed with consolidation chemotherapy. Novel agents for leukemias
refractory to Fludarabine-based regimens are also underway. Blinatu
momab is a bispecific T cell engager monoclonal antibody that is
directed at both CD19 on precursor B cell ALL cells and CD3 on cytotoxic
T cells. It is approved by the European Medicines Agency for treatment
of relapsed/refractory Philadelphia chromosome (Ph) negative precur
sor B cell ALL. The US Food and Drug Administration has also approved
it for relapsed/refractory Ph-negative and Ph-positive precursor B cell
AL. A phase III trial has shown significantly longer overall survival than
chemotherapy [30]. However, the unavailability and cost of this drug is
a major hindrance for use in low income countries. Clofarabine, a

Discussion
Our retrospective study of patients with relapsed ALL or AML being
treated with Fludarabine-based chemotherapy had several insightful
results. With respect to our primary objective, we found a 30-day mor
tality rate of 8%, which is much lower than the 25% reported in a pre
vious study from a similar setting [20]. Complete remission after
therapy was observed in half of the sample (18/35) which is consistent
with previous studies [4, 5, 17, 18]. With respect to our secondary
objective, we did not find any difference in survival between patients on
Fludarabine-based regimens with and without G-CSF, however, patients
on FLAG-IDA has a significantly higher incidence of post-treatment
hepatotoxicity that was not observed in patients treated with FLA-IDA.
Temporary elevation of hepatic enzymes occur in about 10–29% of
patients receiving G-CSF, however, these return to normal once
Table 3
Results of Logistic Regression predicting Complete Remission within 4 weeks.

Molecular genetic risk factor
(present vs. not present)
Risk Stratification (high/
intermediate vs. low)
Cytogenetics (abnormal vs.
normal)
Age
Gender (male vs. female)
Leukemia type (AML vs. ALL)
Chemotherapy Regimen
(FLA-IDA vs. FLAG-IDA)
Initial disease presentation
(Refractory vs. nonrefractory)

β
Coefficient

Standard
Error

Waldscore

pvalue

− 3.614

1.711

4.461

0.035

2.131

1.098

3.765

0.052

− 0.064

0.974

0.004

0.947

0.012
1.830
1.546
1.002

0.036
1.251
1.074
0.985

0.116
2.139
2.072
1.035

0.733
0.144
0.150
0.309

0.563

0.989

0.324

0.569

3
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second-generation purine nucleoside analogue, has shown some prom
ising results for ALL in Phase 2 trials in the pediatric population [31],
and has also shown activity against AML, MDS and chronic myeloid
leukemias in blast phase [32, 33]. Nelarabine, an araguanosine
analogue, has also shown to be very active as a single agent in relapsed
or refractory T-lineage ALL and may also be useful for
Fludarabine-resistant leukemias [34].
This study has several limitations. This is a retrospective study and
hence we cannot determine causality, prospective trials should be
designed in the future to control for additional factors associated with
treatment outcomes. More studies with larger sample size and pro
spective analysis would help us ascertain risk factors that predict the
clinical outcomes. We also have a relatively small sample size with a
short follow-up of 90 days after end of chemotherapy. Future studies
should perform a longer follow-up to see the outcomes after allogenic
stem cell transplantation. Nine patients from our sample remained in
remission up to Day 90 after achieving complete remission on Day 28.
However, not all patients ended up having a transplantation with the
major limiting factor being financial issues, unavailability of matched
donors and personal choice. These factors are common barriers to
treatment of cancers in low- and middle-income countries [35], so it is
not unexpected to also find them in our setting. Future studies should
investigate the common barriers to treatment implementation for acute
leukemias in a low-income setting.

[8]

[9]

[10]

[11]
[12]
[13]
[14]
[15]
[16]
[17]

Conclusion
This retrospective study found the 30-day mortality rate for
Fludarabine-based regimens for adult acute leukemias to be 8%, com
plete remission in 51% of the patients with an acceptable side-effect
profile. This makes it a reasonable choice as salvage chemotherapy to
bridge to stem cell transplant for cases with refractory/relapsed leuke
mia. We also did not find any difference in outcomes between the two
treatment regimens, FLA-IDA and FLAG-IDA, so both appear equally
efficacious and safe for the treatment of refractory/relapsed acute leu
kemias. Good efficacy and manageable toxicity profile are the ideal
properties of this regimen and should be considered to salvage patients
until new therapies in development are available.
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[20]
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